CLCS OTC
New York City, NY 10019
US
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Verstraete George | 0 | — | 2022-03-10 | |
| Soave Darlene | J-Other | 800,000 | $1.25 | 2021-08-09 |
| ZOLTY DAVID | J-Other | 4,860 | $0.75 | 2021-06-30 |
| Soave Darlene | J-Other | 59,507 | $0.75 | 2021-06-30 |
| Brown Dennis M | J-Other | 2,976 | $0.75 | 2021-06-30 |